2025
Short-term estradiol administration does not restore endothelin‐B receptor‐mediated vasodilation in postmenopausal women
Nuckols V, Shoemaker L, Kuczmarski A, Haigh K, McGinty S, Del Vecchio A, Schwab A, Edwards D, Taylor H, Wenner M. Short-term estradiol administration does not restore endothelin‐B receptor‐mediated vasodilation in postmenopausal women. AJP Heart And Circulatory Physiology 2025, 328: h327-h332. PMID: 39773019, PMCID: PMC12175985, DOI: 10.1152/ajpheart.00815.2024.Peer-Reviewed Original ResearchConceptsPostmenopausal womenExogenous estradiol administrationEndothelin B receptorEstradiol administrationPremenopausal womenLactated RingeHealthy postmenopausal womenYoung womenLaser Doppler flowmetryEndothelin-BVasodilatory responseTransdermal patchDoppler flowmetryCutaneous microcirculationVasodilationEstradiolAdministrationWomenReceptorsRingerBlockadeFlowmetry
2018
Long-Term Outcomes of Elagolix in Women With Endometriosis
Surrey E, Taylor HS, Giudice L, Lessey BA, Abrao MS, Archer DF, Diamond MP, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Singh SS, Rechberger T, Agarwal SK, Duan WR, Schwefel B, Thomas JW, Peloso PM, Ng J, Soliman AM, Chwalisz K. Long-Term Outcomes of Elagolix in Women With Endometriosis. Obstetrics And Gynecology 2018, 132: 147-160. PMID: 29889764, DOI: 10.1097/aog.0000000000002675.Peer-Reviewed Original ResearchConceptsMonths of treatmentResponder rateAdverse eventsPlacebo-controlled phase 3 trialGonadotropin-releasing hormone antagonistBone mineral density assessmentCoprimary efficacy endpointsEndometriosis-associated painNonmenstrual pelvic painPelvic pain scoresSafety of elagolixCommon adverse eventsPhase 3 trialProportion of respondersNew safety concernsBone mineral densityClinical laboratory testsElagolix dosesElagolix treatmentEndometrial findingsEfficacy endpointPain scoresPelvic painHot flushesTerm outcomes
2017
Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS)
Taylor HS, Tal A, Pal L, Li F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Du W, Hodis HN, Lobo RA, Manson JE, Merriam GR, Miller VM, Naftolin F, Neal-Perry G, Santoro NF, Harman SM. Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS). JAMA Internal Medicine 2017, 177: 1471-1479. PMID: 28846767, PMCID: PMC5710212, DOI: 10.1001/jamainternmed.2017.3877.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultDouble-Blind MethodEstradiolEstrogen Replacement TherapyEstrogensEstrogens, Conjugated (USP)FemaleFollow-Up StudiesGlucuronatesHumansMiddle AgedPostmenopauseProgesteroneProgestinsProspective StudiesPsychiatric Status Rating ScalesQuality of LifeRisk FactorsSexual Dysfunction, PhysiologicalTime FactorsWomen's HealthConceptsKronos Early Estrogen Prevention StudyLow sexual functionTransdermal estrogen therapySexual functionAncillary studiesEstrogen therapyPostmenopausal womenPrevention StudyT-E2Female Sexual Function InventoryOral conjugated equine estrogenOverall scoreLower FSFI scoresEarly postmenopausal womenMenopausal hormone therapyPlacebo-controlled trialOral micronized progesteroneConjugated equine estrogensSexual Function InventoryLast menstrual periodEffects of OralQuality of lifeProportion of womenSymptoms of distressMicronized progesterone
2016
Effects of hormones on skin wrinkles and rigidity vary by race/ethnicity: four-year follow-up from the ancillary skin study of the Kronos Early Estrogen Prevention Study
Owen CM, Pal L, Mumford SL, Freeman R, Isaac B, McDonald L, Santoro N, Taylor HS, Wolff EF. Effects of hormones on skin wrinkles and rigidity vary by race/ethnicity: four-year follow-up from the ancillary skin study of the Kronos Early Estrogen Prevention Study. Fertility And Sterility 2016, 106: 1170-1175.e3. PMID: 27393520, DOI: 10.1016/j.fertnstert.2016.06.023.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultBlack or African AmericanDouble-Blind MethodDrug CombinationsElasticityEstradiolEstrogen Replacement TherapyEstrogens, Conjugated (USP)FemaleHumansMenopauseMiddle AgedProgesteroneSkinSkin AgingTime FactorsTransdermal PatchTreatment OutcomeUnited StatesWhite PeopleConceptsKronos Early Estrogen Prevention StudyConjugated equine estrogensHormone therapyRace/ethnicityRigidity scoresSkin wrinklesPrevention StudyOral conjugated equine estrogenWhite womenLowest wrinkle scoresPlacebo-controlled trialLast menstrual periodAcademic medical centerBlack womenWrinkle scoreEffects of hormonesEquine estrogensMenopausal womenMenstrual periodMedical CenterMAIN OUTCOMESkin rigidityWomenPlaceboScoresAromatase inhibitor regulates let-7 expression and let-7f–induced cell migration in endometrial cells from women with endometriosis
Cho S, Mutlu L, Zhou Y, Taylor HS. Aromatase inhibitor regulates let-7 expression and let-7f–induced cell migration in endometrial cells from women with endometriosis. Fertility And Sterility 2016, 106: 673-680. PMID: 27320036, PMCID: PMC5831184, DOI: 10.1016/j.fertnstert.2016.05.020.Peer-Reviewed Original ResearchConceptsHuman endometrial stromal cellsLet-7f mimicIshikawa cellsL treatment groupEndometrial cellsAromatase expressionTreatment groupsEndometrial stromal cellsAromatase inhibitor treatmentPathogenesis of endometriosisLet-7f expressionSignificant differencesDose-dependent mannerLetrozole treatmentModulation of microRNAsAromatase inhibitorsLaparoscopic surgeryMAIN OUTCOMEAI treatmentEndometriosisLetrozole concentrationsTherapeutic levelsInhibitor treatmentControl groupTherapeutic potential
2015
Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study
Miller VM, Jenkins GD, Biernacka JM, Heit JA, Huggins GS, Hodis HN, Budoff MJ, Lobo RA, Taylor HS, Manson JE, Black DM, Naftolin F, Harman SM, de Andrade M. Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study. Physiological Genomics 2015, 48: 33-41. PMID: 26508701, PMCID: PMC4757027, DOI: 10.1152/physiolgenomics.00029.2015.Peer-Reviewed Original ResearchConceptsCarotid artery intima-medial thicknessKronos Early Estrogen Prevention StudyMenopausal hormone treatmentCoronary arterial calcificationInnate immunity pathwaysIntima-medial thicknessImmunity pathwaysArterial calcificationPrevention StudySingle nucleotide polymorphismsOral conjugated equine estrogenConjugated equine estrogensTreatment effectsAgatston unitsPlacebo pillsEquine estrogensTreatment outcomesHormonal statusTreatment groupsParticipants 4Hormone treatmentCardiovascular phenotypesPharmacogenomic effectsYr changesEstrogen
2011
Timing and Duration of Menopausal Hormone Treatment May Affect Cardiovascular Outcomes
Harman SM, Vittinghoff E, Brinton EA, Budoff MJ, Cedars MI, Lobo RA, Merriam GR, Miller VM, Naftolin F, Pal L, Santoro N, Taylor HS, Black DM. Timing and Duration of Menopausal Hormone Treatment May Affect Cardiovascular Outcomes. The American Journal Of Medicine 2011, 124: 199-205. PMID: 21396500, PMCID: PMC3107840, DOI: 10.1016/j.amjmed.2010.09.021.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCardiovascular SystemCoronary DiseaseDrug Administration ScheduleEstrogen Replacement TherapyEstrogensFemaleHumansMiddle AgedPostmenopausePrecision MedicineProgestinsRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsThromboembolismTime FactorsWomen's HealthConceptsMenopausal hormone treatmentCoronary heart disease riskHeart disease riskHormone treatmentExcess coronary heart disease riskWomen's Health Initiative hormone trialsDisease riskBeneficial effectsEstrogen-alone trialCoronary heart diseaseYears of treatmentNet harmTreatment-related risksRoute of administrationCurrent FoodShort durationDrug Administration recommendationsDisease incidence ratesWHI dataWHI estrogenWHI findingsCardiovascular outcomesProgestin trialMenopausal symptomsRisk ratio
2009
Using Basic Science to Design a Clinical Trial: Baseline Characteristics of Women Enrolled in the Kronos Early Estrogen Prevention Study (KEEPS)
Miller VM, Black DM, Brinton EA, Budoff MJ, Cedars MI, Hodis HN, Lobo RA, Manson JE, Merriam GR, Naftolin F, Santoro N, Taylor HS, Harman SM. Using Basic Science to Design a Clinical Trial: Baseline Characteristics of Women Enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Journal Of Cardiovascular Translational Research 2009, 2: 228-239. PMID: 19668346, PMCID: PMC2721728, DOI: 10.1007/s12265-009-9104-y.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultCardiovascular DiseasesDouble-Blind MethodEstradiolEstrogen Replacement TherapyEstrogens, Conjugated (USP)FemaleHumansMiddle AgedProgesteroneProspective StudiesPulse Therapy, DrugResearch DesignRisk AssessmentRisk FactorsSex FactorsTime FactorsTranslational Research, BiomedicalTreatment OutcomeUnited StatesWomen's HealthConceptsKronos Early Estrogen Prevention StudyMenopausal hormone therapyClinical trialsEpidemiological studiesWomen's Health Initiative hormone trialsEstrogen Replacement StudyYears of menopauseCardiovascular disease riskProgression of atherosclerosisDemographics of womenBasic science studiesTiming of initiationMechanism of actionKEEP participantsMHT useBaseline characteristicsHormone therapyProspective trialPrevention StudyHormone trialsCardiovascular diseaseBasic science informationDisease riskParticipant demographicsAdverse effects
2008
Defining the proliferative phase endometrial defect
Bromer JG, Aldad TS, Taylor HS. Defining the proliferative phase endometrial defect. Fertility And Sterility 2008, 91: 698-704. PMID: 18314107, PMCID: PMC2699408, DOI: 10.1016/j.fertnstert.2007.12.066.Peer-Reviewed Original ResearchMeSH KeywordsAbortion, HabitualAdultClomipheneEndometriosisEndometriumFemaleFertility Agents, FemaleFertilization in VitroFollicle Stimulating HormoneFollicular PhaseHumansInfertility, FemaleInsemination, ArtificialMiddle AgedOvulation InductionPolycystic Ovary SyndromePregnancyPregnancy RateRetrospective StudiesRisk FactorsTime FactorsTreatment OutcomeUltrasonographyYoung AdultConceptsEndometrial thicknessCycle day 9Endometrial developmentDay 9Hormone-stimulated cyclesMaximum endometrial thicknessPeak endometrial thicknessClinical pregnancy ratePolycystic ovary syndromeRecurrent pregnancy lossBody mass indexClomiphene citrate cyclesCycle day 4Endometrial defectClomiphene citrateOvarian stimulationInfertility populationOvary syndromeEndometrial growthTransvaginal ultrasonographyMass indexInfertility practiceRetrospective studyControl subjectsPregnancy loss
2007
Demonstration of Multipotent Stem Cells in the Adult Human Endometrium by In Vitro Chondrogenesis
Wolff EF, Wolff AB, Du H, Taylor HS. Demonstration of Multipotent Stem Cells in the Adult Human Endometrium by In Vitro Chondrogenesis. Reproductive Sciences 2007, 14: 524-533. PMID: 17959881, DOI: 10.1177/1933719107306896.Peer-Reviewed Original ResearchConceptsEndometrial stromal cellsMultipotent stem cellsFallopian tubeType II collagenStem cellsReproductive-aged womenHuman articular cartilageEndometrial stem cellsAdult human endometriumII collagenMultilineage differentiationArticular cartilageBenign diseaseEndometrial tissueExtramedullary tissuesHuman endometriumCell pelletsEndometriumChondrogenic mediumStromal cellsLigament cellsSulfated glycosaminoglycansGrowth factorProgenitor cellsCell typesIndividual dose response of insulin resistance to estrogen therapy.
Jovanovic K, Taylor HS. Individual dose response of insulin resistance to estrogen therapy. The Journal Of Reproductive Medicine 2007, 52: 667-9. PMID: 17879825.Peer-Reviewed Original ResearchConceptsConjugated equine estrogensQuantitative insulin sensitivity check indexInsulin resistanceGlucose/insulin ratioDose responseInsulin sensitivity check indexIndividual dose responsesDoses of estrogenSubjects meeting inclusion criteriaMonths of treatmentMeeting inclusion criteriaEstrogen therapySerum insulinEquine estrogensInsulin ratioCheck indexInclusion criteriaIndividual patientsGlucose levelsEstrogenRandom orderMonthsSignificant changesFirst studySingle subject
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply